Literature DB >> 3264405

Prevention of diabetes in nonobese diabetic mice by anti-I-A monoclonal antibodies: transfer of protection by splenic T cells.

C Boitard1, A Bendelac, M F Richard, C Carnaud, J F Bach.   

Abstract

The nonobese diabetic (NOD) mouse has been developed as a model for insulin-dependent diabetes. One gene required for the development of diabetes is associated with the major histocompatibility complex. This gene possibly could be linked to class II genes, which show a unique pattern in NOD mice. To evaluate the role of the I-A class II antigen expressed in NOD mice, we studied the effect of anti-I-A monoclonal antibodies on disease onset in vivo. Long-term treatment with anti-class II IgG2a antibodies specific for NOD I-A antigen prevented the spontaneous development of diabetes, as opposed to control antibodies shown not to react with NOD I-A antigen. Anti-class II antibodies apparently elicited active immune suppression, requiring a fully immunocompetent host, rather than passive blockade of class II antigen. Treatment with anti-class II antibody effectively prevented the adoptive transfer of diabetes produced by splenocytes from diabetic NOD mice into newborn mice but failed to prevent adoptive transfer into irradiated adult NOD recipients. Direct evidence for the induction of suppressor cells was obtained from the passive transfer of spleen cells from anti-class II antibody-treated NOD donors. The injection of anti-class II antibody-treated spleen cells collected from NOD donors prevented the development of diabetes, which normally follows transfer of diabetogenic spleen cells into irradiated 8-week-old male NOD recipients. Depletion experiments indicate that CD4+ cells are responsible for anti-class II-induced protection transferred by spleen cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264405      PMCID: PMC282848          DOI: 10.1073/pnas.85.24.9719

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Genetic control of the immune response to myoglobins. IV. Inhibition of determinant-specific Ir gene-controlled antigen presentation and induction of suppression by pretreatment of presenting cells with anti-Ia antibodies.

Authors:  J A Berzofsky; L K Richman
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

2.  Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and Ia antigens.

Authors:  V T Oi; P P Jones; J W Goding; L A Herzenberg; L A Herzenberg
Journal:  Curr Top Microbiol Immunol       Date:  1978       Impact factor: 4.291

3.  Antigen-specific human T lymphocyte clones: mechanisms of inhibition of proliferative responses by xenoantiserum to human nonpolymorphic HLA-DR antigens.

Authors:  J R Lamb; D D Eckels; E A Ketterer; T W Sell; J N Woody
Journal:  J Immunol       Date:  1982-09       Impact factor: 5.422

4.  Monoclonal antibodies reacting with murine teratocarcinoma cells.

Authors:  P N Goodfellow; J R Levinson; V E Williams; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

5.  Hybridoma cell lines secreting monoclonal antibodies to mouse H-2 and Ia antigens.

Authors:  K Ozato; N Mayer; D H Sachs
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

6.  Breeding of a non-obese, diabetic strain of mice.

Authors:  S Makino; K Kunimoto; Y Muraoka; Y Mizushima; K Katagiri; Y Tochino
Journal:  Jikken Dobutsu       Date:  1980-01

7.  Participation of suppressor T cells in the immunosuppressive activity of a heteroantiserum to human Ia-like antigens (p23,30).

Authors:  S Broder; D L Mann; T A Waldmann
Journal:  J Exp Med       Date:  1980-01-01       Impact factor: 14.307

8.  In vivo effects of antibodies to immune response gene products. I. Haplotype-specific suppression of humoral immune responses with a monoclonal anti-I-A.

Authors:  J T Rosenbaum; N E Adelman; H O McDevitt
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

9.  Conversion of immunity to suppression by in vivo administration of I-A subregion-specific antibodies.

Authors:  L L Perry; M I Greene
Journal:  J Exp Med       Date:  1982-08-01       Impact factor: 14.307

10.  Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition.

Authors:  J W Kappler; B Skidmore; J White; P Marrack
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

View more
  34 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 2.  Genetic analysis of susceptibility to type 1 diabetes.

Authors:  J A Todd
Journal:  Springer Semin Immunopathol       Date:  1992

Review 3.  The differentiation of the immune system towards anti-islet autoimmunity. Clinical prospects.

Authors:  C Boitard
Journal:  Diabetologia       Date:  1992-12       Impact factor: 10.122

Review 4.  Non-obese diabetic transgenic mouse.

Authors:  K Yamamura; T Miyazaki; M Uno; T Toyonaga; J Miyazaki
Journal:  Springer Semin Immunopathol       Date:  1992

5.  Peripherin: an islet antigen that is cross-reactive with nonobese diabetic mouse class II gene products.

Authors:  C Boitard; M C Villa; C Becourt; H P Gia; C Huc; P Sempe; M M Portier; J F Bach
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

Review 6.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

7.  Inhibition of murine nephritogenic effector T cells by a clone-specific suppressor factor.

Authors:  C M Meyers; C J Kelly
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

8.  Thymus reticulum of autoimmune mice. 3. Ultrastructural study of NOD (non-obese diabetic) mouse thymus.

Authors:  B Nabarra; I Andrianarison
Journal:  Int J Exp Pathol       Date:  1991-06       Impact factor: 1.925

Review 9.  Type 1 diabetes mellitus: an imbalance between effector and regulatory T cells?

Authors:  E J Rashba; E P Reich; C A Janeway; R S Sherwin
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

10.  Pancreatic NOD beta cells express MHC class II protein and the frequency of I-A(g7) mRNA-expressing beta cells strongly increases during progression to autoimmune diabetes.

Authors:  U Walter; T Toepfer; K E J Dittmar; K Kretschmer; J Lauber; S Weiss; G Servos; O Lechner; W A Scherbaum; S R Bornstein; H Von Boehmer; J Buer
Journal:  Diabetologia       Date:  2003-07-10       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.